SARS-CoV-2 antibody test moving to the next development phase

22. Jan 2021 | 2 min read

Moss, 22.01.2021

Gentian Diagnostics AS is pleased to announce that its high-throughput
SARS-CoV-2 antibody test project has moved from the proof-of-concept phase to
the project initiation and optimisation phase. An official project plan has been
established with an approved budget and a dedicated project team, moving the
project forward. The timeline to launch is set to Q4 2021.

The aim for the SARS-CoV-2 antibody test is to offer the first assay on
high-throughput open-access clinical chemistry platforms, that supports
vaccination efforts and aid in community management by the determination of
immunisation status.

The project is supported by the collaboration with Professor Ørjan Olsvik and
Dr. Vegard Skogen at the University of Tromsø, The Arctic University of Norway,
providing expertise and guidance regarding SARS-CoV-2 research and vaccination

Gentian’s CEO Dr. Hilja Ibert commented: “This is truly an outstanding
achievement. Our R&D team has managed to bring this marker into the optimisation
phase in record time and with the participation from our collaborating partners
we will move forward with the assay development."

For further information contact:

Hilja Ibert CEO, Gentian Diagnostics
Cell Phone: +47 919 05 242

Njaal Kind CFO, Gentian Diagnostics
Cell Phone: +47 919 06 525


MeldingsID: 523005
UtstederID: GENT
Marked: Euronext Growth (Oslo)

You may also read

Aug 19, 2021 - Kristin Hart

Invitation to presentation of second quarter results

Gentian Diagnostics ASA will present its 2021 second quarter results on August 25th at 10.00 am. The..

Jun 25, 2021 - Kristin Hart

Gentian Diagnostics was today listed on the Oslo Stock Exchange

“We made a promise to our shareholders when we were listed on Euronext Growth that we would aim for the main..